Document is current
Any future updates will be listed below
-
Authors
Dube, Christabel Thembela https://orcid.org/0000-0001-8155-5793
Gilbert, Hamish T. J. https://orcid.org/0000-0003-2571-765X
Rabbitte, Niamh
Baird, Pauline
Patel, Sonal
Herrera, Jeremy A. https://orcid.org/0000-0003-4845-8494
Baricevic-Jones, Ivona
Unwin, Richard D. https://orcid.org/0000-0001-7955-9111
Chan, Danny https://orcid.org/0000-0003-3824-5778
Gnanalingham, Kanna
Hoyland, Judith A. https://orcid.org/0000-0003-4876-5208
Richardson, Stephen M. https://orcid.org/0000-0002-7637-4135
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/W019418/1, MR/W019418/1, MR/M008959/1, MR/M008959/1, MR/W019418/1, MR/W019418/1)
ECMage Network (E&M/R1/08, E&M/R1/08, E&M/R1/08)
Faculty of Biology, Medicine and Health Research Development Award
RGC European Union - Hong Kong Research and Innovation Cooperation Co-funding Mechanism (E-HKU703/18)
Manchester Academic Health Science Centre
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 26 January 2025
First Online: 10 February 2025
Declarations
:
: All donors provided full written informed consent before tissue collection. This study was reviewed and approved by the National Research Ethics Service Committee North West (REC reference: 17/LO/1408).
: Not applicable.
: RDU is a founder and shareholder of Complement Therapeutics Inc (CTx), which is developing complement-targeted therapies initially in ocular disease. CTx played no role in the design, execution or analysis of this study. The remaining authors declare no competing interests.
